ClinicalTrials.gg

Respiratory Insufficiency clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,370 studies for Respiratory Insufficiency across more than 10 countries. 265 are recruiting or about to start. 804 of them are mainly about Respiratory Insufficiency (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-16. Counting its 7 narrower conditions too, such as Nasal Obstruction: 1,883 studies, 366 open.

ClinicalTrials.gov finds 3,035 studies for Respiratory Insufficiency. How that becomes 1,370 here

This page counts the studies the registry files under Respiratory Insufficiency, and those it files under no condition that list Respiratory Insufficiencythemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 17, 2026. How condition pages count

  1. 3,035Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −504Filed under a narrower condition, counted on its own pageNasal Obstruction 170 · Airway Obstruction 138 · Hypoventilation 73 · Obesity Hypoventilation Syndrome 59 · Respiratory Paralysis 32 · Patient-Ventilator Asynchrony 18 · 1 more
  3. −24List Respiratory Insufficiency as a condition, but the registry did not file them under itMost often written as “Chronic Respiratory Insufficiency” (7), “Respiratory Insufficiency Syndrome of Newborn” (5), and “Chronic Hypercapnic Respiratory Failure” (4). The registry filed them under other conditions only, most often Pulmonary Disease, Chronic Obstructive (7) and Bronchopulmonary Dysplasia (3).
  4. −1,137Match it another way74 name it in the title, 3 in a keyword, and 1,060 by a synonym or other text the search reads.
  5. 1,370The count on this page22 of them list Respiratory Insufficiency in their own words; the registry filed them under no condition.

Status

Completed
701
Status unknown
214
Recruiting
180
Terminated
96
Not yet recruiting
74
Withdrawn
47

Phase

Phase 2
86
Phase 3
79
Phase 4
59
Phase 1
36
Early Phase 1
6

Where

United States
349
France
127
Italy
112
Canada
94
China
92
Spain
69

Who develops what

Add Respiratory Insufficiency to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 2 programs from 2 companies, 1 with this as their studies’ main aim; 0 with a live phase 3 study; 2 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

None given by two companies or more yet.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 2 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (2)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Jun 2027 est.Allogeneic Invariant Natural Killer T-cells agenT-797 · MiNK Therapeutics · Phase 2 named, not the main aimNCT07615010 A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure — primary endpoint: Number of Deaths (All-cause Mortality) · 90 enrolled
  • 15 Jun 2027 est.GAL021 · Enalare Therapeutics Inc. · Phase 2 main aimNCT06137638 ENA-001 for Post Operative Respiratory Depression (PORD) — primary endpoint: To evaluate the effects of ENA-001 on pulmonary ventilation when administered to 100 subjects via continuous infusion of a loading dose of 2.0 mg/kg/hr for 20 minutes followed by a maintenance dose of 1.1 mg/kg/hr · 200 enrolled

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Respiratory Insufficiency studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Opioids 2 open · Neuromuscular blockers 2 open · Stimulants 2 open · Corticosteroids 1 open · NSAIDs 5

Coming up

97studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Who these studies take

Of the 180 Respiratory Insufficiency studies recruiting now, 135 (75%) set no upper age limit and 18 (10%) stop at 75 or younger. 21 (12%) take children under 18. 1 (1%) are for women only and 1 (1%) for men only; 20 (11%) take healthy volunteers.

Recruiting studies that take each age, of 180
AgeWomenMen
1015 (8%)15 (8%)
18164 (91%)164 (91%)
30166 (92%)166 (92%)
40167 (93%)167 (93%)
50167 (93%)167 (93%)
65167 (93%)167 (93%)
75165 (92%)165 (92%)
85154 (86%)154 (86%)

Across all 1,370 studies, recruiting or not: 18% stop at 75 or younger and 15% at 65; 17% take children; 2% are for women only and <1% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Respiratory Insufficiency studies take

Of 30 phase 2 interventional studies under Respiratory Insufficiency, half reached primary completion within 12 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 111 mo3–16 · 12 studies——
Phase 212 mo10–37 · 30 studies——
Phase 325 mo12–53 · 21 studies——
Phase 414 mo7–25 · 23 studies——
Interventional, no phase24 mo10–46 · 376 studies—24 mo11–47 · 360 studies
Observational22 mo12–44 · 248 studies—22 mo12–54 · 232 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Studies

Recruiting first, then most recently updated. Showing 50 of 1,370. Browse all 1,370 → or search them.